• Home
  • Research areas
    • ADME-Tox
    • Biomarkers
    • Cell Biology and Signalling
    • Cell Sourcing – Cell Culture Technologies
    • Drug Discovery
    • Gene Expression – Molecular Biology
    • Stem Cells
    • Supplying Discovery Tools
  • Contact us
  • Meet the authors
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Home
Research areas
    ADME-Tox
    Biomarkers
    Cell Biology and Signalling
    Cell Sourcing - Cell Culture Technologies
    Drug Discovery
    Gene Expression - Molecular Biology
    Stem Cells
    Supplying Discovery Tools
Contact us
Meet the authors
tebu-bio's blog - Acting and reacting in life sciences and biotechnologies
  • Home
  • Research areas
    • ADME-Tox
    • Biomarkers
    • Cell Biology and Signalling
    • Cell Sourcing – Cell Culture Technologies
    • Drug Discovery
    • Gene Expression – Molecular Biology
    • Stem Cells
    • Supplying Discovery Tools
  • Contact us
  • Meet the authors
Drug Discovery

Immunotherapy Screening – B7-1 / CD28 and B7-1 / CTLA4 Pathways in Drug Discovery

01/07/2014 by Ali El Baya, PhD No Comments

The treatment of diseases by inducing, enhancing, or surpressing an immune response is referred to as Immunotherapy. T-cell activation and inactivation requires the coordination of various co-inhibitory and co-stimulatory signals and most immunotherapies modulate these signals.

Therapeutic manipulation of immunopathways has lead to promising clinical results for the treatment of a number of diseases such as cancer, autoimmune diseases and inflammatory diseases. Research in this field is rapidly evolving as scientists seek to identify the next generation of therapies.

In the first post of a series of three,  I will describe the B7-1 : CD28 and B7-1 : CTLA4 pathways and summarize the portfolio of tools currently available to researchers to investigate these pathways. In fact, these are the first kits on the market to screen for inhibitors of these pathways.

Continue reading
Drug Discovery, Supplying Discovery Tools

How to measure Calcium in cell based assays?

30/06/2014 by Ali El Baya, PhD No Comments

In Pharma screening departments there is a strong need for Ca2+ measurement methods.

Why is this?

GPCR - Calcium mobilisation

GPCRs (G Protein Coupled Receptors) are still major targets of pharmaceutical screenings.

Around 30-40% of all drugs on the market are directed against GPCRs.

Drugs have an impact on the GPCR activity and thus the downstream signal transduction cascade. GPCRs are linked to the activity of heterotrimeric G proteins which consist of alpha, beta and gamma subunits. These G proteins have an effect on PhosphoLipase C (PLC) which leads to the release of Inositol Phosphate 3 (IP3) which finally leads to intracellular Ca2+ mobilization (release from the endoplasmic reticulum ) – Ca2+ finally has effect on a number of further cellular processes.

The fact that GPCR activation always leads to Ca2+mobilization is commonly used to indirectly measure the impact of compounds/drug candicates on GPCRs.

Hence the need for Ca2+ measurement methods, such as the following…

Continue reading
ADME-Tox, Cell Sourcing - Cell Culture Technologies, Drug Discovery

Plateable Hepatocytes… the "one cell type doesn't fit all" syndrome

27/06/2014 by Jean-François Têtu, PhD No Comments

Hepatocytes are commonly used in drug discovery and preclinical drug development to perform experiments requiring intact cellular systems. Intact hepatocytes contain the major hepatic drug-metabolizing enzymes required to study the four categories of xenobiotic biotransformation: Hydrolysis, Reduction, Oxidation and Conjugation. Because of these enzymes, hepatocytes provide a viable and cost-effective alternative to in vivo compound testings.

Continue reading
Cell Sourcing - Cell Culture Technologies, Drug Discovery, Headlines, Supplying Discovery Tools

Isogenic Knockout iPSC Lines for Modeling of CNS Disorders

13/06/2014 by Jean-François Têtu, PhD No Comments
Live staining astrocytes derived from knock‐in reporter line for GFAP

Live staining astrocytes derived from knock‐in reporter line for GFAP

Somatic cell reprogramming technology enables researchers to build disease models by generating iPSC lines from patient samples, to differentiate them into targeted primary cells, and manifest disease symptoms in vitro.

So far, many disease models for CNS disorders, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Autism, Schizophrenia, and Amyotrophic Lateral Sclerosis (ALS), have been generated using this strategy. However, there is a common limitation for disease models solely based on patient‐derived iPSC lines: the mechanism of action of genetic mutations underlying a disease is often complicated by diverse genetic backgrounds from patient to patient since most genetic mutations associated with CNS disorders have in general small effect on the disease phenotype.

Continue reading
Page 20 of 22« First...10«19202122»
tebu-bio

LAB SERVICES OUTSOURCING

• Protein production

• Plasmid Preps

• 3D Cell Culture
LEARN MORE

Most popular posts

  • HeLa cells: Origin of this important cell line in life science research
  • From RUO to IVD - the acronym guide to reagents' intended use
  • How to choose the perfect buffer to get a pure, stabilised, functional protein
My Tweets

Top contributors

Dimitri Szymczak, PhD
Dimitri Szymczak, PhD
  • How can you get your mRNA ready in only a few weeks?
  • CleanCap: The new capping standard for self-amplifying mRNA
Frédéric Samazan
Frédéric Samazan
  • Immuno-Oncology: 6 must-haves to boost your projects
  • MagIC Beads – The future of RNA capture kits
Isabelle Nobiron, PhD
Isabelle Nobiron, PhD
  • COVID-19: relevant cell culture models
  • Immunoassay development: reliable sources of quality reagents
Isabelle Topin, PhD
Isabelle Topin, PhD
  • Antibody Purification: Tips and Tricks
  • Monoclonal antibodies – all you need to know about antibody generation
Philippe Fixe, PhD
Philippe Fixe, PhD
  • How to monitor inflammatory cytokines in anti-COVID drug discovery
  • New SARS-CoV/ACE2 inhibitor assays & small molecules for drug discovery

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Copyright © 2018 - tebu-bio - visit our main website at tebu-bio.com